Categorynews

Eric Bernabei Joins Avellino Labs as Chief Sales and Marketing Officer

April 16, 2019 Off By BusinessWire

Bernabei’s Global Clinical and Commercial Experience to Shape Strategic
Direction of Genetic Diagnostic and Therapeutic Technology Company’s
Growth in Ophthalmology

MENLO PARK, Calif.–(BUSINESS WIRE)–Avellino Labs, global biotechnology and genetic science innovators,
announced today Eric Bernabei has joined the company as chief sales and
marketing officer (CSMO). Bernabei, who brings more than 20 years of
clinical and commercial ophthalmic experience to the role, will inform
and implement the strategic expansion of Avellino Labs’ disruptive
genetic diagnostic and therapeutic technologies in support of the
company’s global leadership in the genetics and ophthalmic sectors.

Bernabei joins Avellino Labs after his most recent roles as global
product and strategic marketing director with Alcon. Throughout his
career, Bernabei has focused on introducing new and advanced eye care
technologies in various global, regional and country level leadership
roles. With his global experience and relationships with ophthalmic
thought leaders, Bernabei will help translate the value of Avellino’s
genomic technology to clinicians and shape market adoption.

“Eric truly understands what is driving the success of Avellino Labs in
our best markets like Korea, and he will put the right partnerships and
strategies in place to guide our growth in U.S. and European markets,”
said Avellino Labs chairman of the board, Gene Lee. “His trusted
expertise has made a tremendous impact on the advancement of several
innovative ophthalmic technologies around the globe, which will be
important to Avellino moving forward.”

In his new role, Bernabei’s immediate focus will be the development of a
strategic marketing program focused on the growth of Avellino Labs’
expanding genetic service offerings and has tapped leading specialty
marketing firm HCB Health to support the initiative.

Before joining Avellino Labs, Bernabei actively managed multinational
marketing and sales initiatives for medical device and pharmaceutical
organizations, including extended in-market assignments in Asia and
Europe for Alcon following clinical support roles at Becton Dickinson
and Summit Technology.

“I have been very fortunate to have been involved in the launch of some
transformative cataract and refractive technologies and look forward to
changing how doctors approach the diagnosis and treatment of disease in
ophthalmology with Avellino,” said Bernabei. “Our goal is to identify
the best way to bring personalized medicine into each country and
culture, uncover what resonates deepest with physicians and patients,
and leverage Avellino’s genetic testing and therapeutics to address the
global unmet needs in ophthalmology.”

About Avellino Labs

Avellino Labs is a global leader in gene therapy and molecular
diagnostics and the pioneer in personalized medicine for eye care.
Avellino Labs is pioneering CRISPR gene editing to manage and
potentially cure inherited diseases. Avellino Labs continues to expand
its diagnostics capabilities, building on the success of the world’s
first DNA test to confirm the presence of genetic indicators that are
positively associated with corneal dystrophies, providing life-changing
information for patient treatment decisions and follow-up care. Avellino
Labs is headquartered in Silicon Valley, California, with operations in
Korea, Japan, China and the UK.

Avellino Labs was named a 2015 Technology Pioneer by the World Economic
Forum based on its potential to impact global health.

To learn more, please visit http://www.avellino.com/us/
or follow us on Twitter @Avellinolab_USA.